Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EP4808] to GABARAPL2/GATE-16
  • Suitable for: WB
  • Knockout validated
  • Reacts with: Human

Overview

  • Product name

    Anti-GABARAPL2/GATE-16 antibody [EP4808]
    See all GABARAPL2/GATE-16 primary antibodies

  • Description

    Rabbit monoclonal [EP4808] to GABARAPL2/GATE-16

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human GABARAPL2/GATE-16 aa 50-150. The exact sequence is proprietary.

  • Positive control

    • HeLa, Human fetal brain, Human heart and Human spleen lysates.

  • General notes

    Previously labelled as GABARAPL2. 

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

Images

  • Western blot - Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)
    Western blot - Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)

    Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: GABARAPL2 / GATE-16 knockout HAP1 cell lysate (20 µg)
    Lane 3: HeLa cell lysate (20 µg)
    Lane 4: Human tonsil lysate (20 µg)
    Lanes 1 - 4: Merged signal (red and green). Green - ab126607 observed at 15 kDa. Red - loading control, ab8245, observed at 37 kDa.

    ab126607 was shown to specifically react with GABARAPL2 / GATE-16 when GABARAPL2 / GATE-16 knockout samples were used. Wild-type and GABARAPL2 / GATE-16 knockout samples were subjected to SDS-PAGE. ab126607 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

  • Western blot - Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)
    Western blot - Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)
    All lanes : Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607) at 1/1000 dilution

    Lane 1 : Human fetal brain tissue lysate
    Lane 2 : Human heart tissue lysate
    Lane 3 : HeLa cell lysate
    Lane 4 : Human spleen tissue lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat anti-Rabbit HRP at 1/2000 dilution

    Predicted band size: 14 kDa
    Observed band size: 14 kDa

  • OI-RD Scanning - Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)
    OI-RD Scanning - Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)
    Equilibrium disassociation constant (KD)
    Learn more about KD

    Click here to learn more about KD
  • Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)
    Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-GABARAPL2/GATE-16 antibody [EP4808] (ab126607)

© 2021 Astana Biomed Group LLP. All rights reserved.